Viral Vector Manufacturing Market by Application (Vaccinology, Gene Therapy), Type (AAV), Retrovirus, Gammaretrovirus, Disease (Infectious Disease, Cancer, Genetic Disorders), End User (Research Institutes, Biotech companies) – 2020 to 2025

$3,850.00$5,850.00

AVAIL 20% DISCOUNT ON PURCHASE OF ANY REPORT
Published on: March 23, 2020
Clear
SKU: GMS-2088 Category:

The global manufacturing market for viral vector is expected to hit USD 1,321 million by 2025, rising over the forecast period at a CAGR of 19.1 per cent. Some primary factors driving market growth include the growing prevalence of target diseases and disorders, the availability of funding for the production of gene therapy, the efficacy of viral vectors in the delivery of gene therapy and ongoing research into gene & cell therapies based on viral vectors.

Viral Vector Manufacturing Market by Application (Vaccinology, Gene Therapy), Type (AAV), Retrovirus, Gammaretrovirus, Disease (Infectious Disease, Cancer, Genetic Disorders), End User (Research Institutes, Biotech companies) - 2020 to 2025 2

Viral Vector Manufacturing Market by Application (Vaccinology, Gene Therapy), Type (AAV), Retrovirus, Gammaretrovirus, Disease (Infectious Disease, Cancer, Genetic Disorders), End User (Research Institutes, Biotech companies) - 2020 to 2025 3

Viral Vector Manufacturing Market by Application (Vaccinology, Gene Therapy), Type (AAV), Retrovirus, Gammaretrovirus, Disease (Infectious Disease, Cancer, Genetic Disorders), End User (Research Institutes, Biotech companies) - 2020 to 2025 4

Viral Vector Manufacturing Market by Application (Vaccinology, Gene Therapy), Type (AAV), Retrovirus, Gammaretrovirus, Disease (Infectious Disease, Cancer, Genetic Disorders), End User (Research Institutes, Biotech companies) - 2020 to 2025 5

Viral Vector Manufacturing Market by Application (Vaccinology, Gene Therapy), Type (AAV), Retrovirus, Gammaretrovirus, Disease (Infectious Disease, Cancer, Genetic Disorders), End User (Research Institutes, Biotech companies) - 2020 to 2025 6

Viral Vector Manufacturing Market by Application (Vaccinology, Gene Therapy), Type (AAV), Retrovirus, Gammaretrovirus, Disease (Infectious Disease, Cancer, Genetic Disorders), End User (Research Institutes, Biotech companies) - 2020 to 2025 7

Viral Vector Manufacturing Market by Application (Vaccinology, Gene Therapy), Type (AAV), Retrovirus, Gammaretrovirus, Disease (Infectious Disease, Cancer, Genetic Disorders), End User (Research Institutes, Biotech companies) - 2020 to 2025 8

Viral Vector Manufacturing Market by Application (Vaccinology, Gene Therapy), Type (AAV), Retrovirus, Gammaretrovirus, Disease (Infectious Disease, Cancer, Genetic Disorders), End User (Research Institutes, Biotech companies) - 2020 to 2025 9

1 Global Viral Vector Manufacturing Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 Global Viral Vector Manufacturing Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 Global Viral Vector Manufacturing Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis

5 Global Viral Vector Manufacturing Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies

6 Global Viral Vector Manufacturing Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes

7 Global Viral Vector Manufacturing Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)

8 Global Viral Vector Manufacturing Market – By Type (Market Size – & million/billion)
8.1 Retroviral Vectors
8.2 Adenoviral Vectors
8.3 Adeno-associated Viral Vectors
8.4 Other

9 Global Viral Vector Manufacturing Market – By Disease
9.1 Cancers
9.2 Genetic Disorders
9.3 Infectious diseases
9.4 Other

10 Global Viral Vector Manufacturing Market – By Application
10.1 Gene Therapy
10.2 Vaccinology

11 Global Viral Vector Manufacturing Market – By End-User
11.1 Pharmaceutical and Biopharmaceutical Companies
11.2 Research Institutes

12 Global Viral Vector Manufacturing Market – By Geography (Market Size – &
million/billion)
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 U.K
12.3.2 Germany
12.3.3 Italy
12.3.4 France
12.3.5 Spain
12.3.6 Rest of Europe
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 South Korea
12.4.5 Rest of APAC
12.5 Rest of the World
12.5.1 South America
12.5.2 Middle East
12.5.3 Africa

13 Global Viral Vector Manufacturing Market – Entropy
13.1 New product launches
13.2 M&A’s, collaborations, JVs and partnerships

14 Global Viral Vector Manufacturing Market Company Profile (Key Players)
14.1 Market Share, Company Revenue, Products, M&A, Developments
14.2 Merck KGaA
14.3 Oxford Biomedica
14.4 Cobra Biologics
14.5 Cell and Gene Therapy Catapult (CGT Catapult)
14.6 Fujifilm Holdings Corporation
14.7 Novasep
14.8 Spark Therapeutics
14.9 Kaneka Eurogentec
14.10 Finvector Vision Therapies
14.11 Brammer Bio
14.12 Company 11 & more

15 Global Viral Vector Manufacturing Market – Appendix
15.1 Sources
15.2 Abbreviations